{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:41:29Z","timestamp":1794613289455,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteonecrosis of the jaw (ONJ) is a rare but serious adverse drug reaction (ADR) commonly associated with bisphosphonate and denosumab therapy. Prior research utilized an online, public FDA Adverse Event Reporting System (FAERS) Database to explore this ADR. This data identified and described several novel medications associated with ONJ. Our study aims to build upon the prior findings, reporting trends of medication induced ONJ over time and identifying newly described medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched the FAERS database for all reported cases of medication related osteonecrosis of the jaw (MRONJ) from 2010 to 2021. Cases lacking patient age or gender were excluded. Only adults (18\u2009+) and reports from Healthcare Professions were included. Duplicate cases were removed. The top 20 medications were identified and described for April 2010-December 2014 and April 2015-January 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen thousand six hundred sixty-eight cases of ONJ were reported to the FAERS database from 2010\u20132021. 8,908 cases met inclusion criteria. 3,132 cases were from 2010\u20132014 and 5,776 cases from 2015\u20132021. Within the cases from 2010\u20132014, 64.7% were female and 35.3% were male, and the average age was 66.1\u2009\u00b1\u200911.1\u00a0years. Between 2015\u20132021, 64.3% were female and 35.7% were male, and the average age was 69.2\u2009\u00b1\u200911.5\u00a0years. Review of the 2010\u20132014 data identified several medications and drug classes associated with ONJ not previously described. They include lenalidomide, corticosteroids (prednisolone and dexamethasone), docetaxel and paclitaxel, letrozole, methotrexate, imatinib, and teriparatide. Novel drugs and classes described between 2015\u20132021 include palbociclib, pomalidomide, radium 223, nivolumab, and cabozantinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>While stricter inclusion criteria and removal of duplicate cases led to fewer overall identified cases of MRONJ when compared to prior research, our data represents a more reliable analysis of MRONJ reports to the FAERS database. Denosumab was the most frequently reported medication associated with ONJ. While unable to imply incidence rates from our data due to the nature of the FAERS database, our findings provide further description of the various medications associated with ONJ and elucidate patient demographics associated with the ADR. Additionally, our study identifies cases of several newly described drugs and drug classes that have not been previously described in literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-023-00657-y","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:13:45Z","timestamp":1678086825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5943-5293","authenticated-orcid":false,"given":"Hardeep S.","family":"Ahdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Adam","family":"Wichelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasirekha","family":"Pandravada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli D.","family":"Ehrenpreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"657_CR1","unstructured":"Ganesan K, Bansal P, Goyal A, et al. \u201cBisphosphonate.\u201d StatPearls. Treasure Island (FL): StatPearls Publishing; updated 2021 Jul 6. Accessed date 26 Sept 2021."},{"key":"657_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341\u20137.","journal-title":"Ann Oncol"},{"key":"657_CR3","unstructured":"American Association of Oral and Maxillofacial Surgeons. 2014. Medication-Related Osteonecrosis of the Jaw-2014 Update. Retrieved from https:\/\/www.aaoms.org\/docs\/govt_affairs\/advocacy_white_papers\/mronj_position_paper.pdf. Accessed date 10\/07\/2021."},{"issue":"2","key":"657_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jbmr.2693","volume":"31","author":"X Zhang","year":"2016","unstructured":"Zhang X, Hamadeh I, Song S, et al. Osteonecrosis of the Jaw in the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS). J Bone Miner Res. 2016;31(2):336\u201340.","journal-title":"J Bone Miner Res"},{"key":"657_CR5","doi-asserted-by":"publisher","first-page":"160026","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"J Banda","year":"2016","unstructured":"Banda J, Evans L, Vanguri R, et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3:160026.","journal-title":"Sci Data"},{"issue":"5","key":"657_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/ph14050425","volume":"14","author":"JY Choi","year":"2021","unstructured":"Choi JY, Choi JH, Kim MG, et al. Signal Detection of Adverse Drug Reactions of Cephalosporins Using Data from a National Pharmacovigilance Database. Pharmaceuticals (Basel). 2021;14(5):425.","journal-title":"Pharmaceuticals (Basel)"},{"key":"657_CR7","unstructured":"Gupta, Mohit and Gupta, Neha. \u201cBisphosphonate Related Jaw Osteonecrosis.\u201d StatPearls. StatPearls Publishing; updated 2021 Jul 28. Accessed date 7 Oct 2021."},{"issue":"2","key":"657_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3892\/mco.2016.1100","volume":"6","author":"D Yamamoto","year":"2017","unstructured":"Yamamoto D, et al. Osteonecrois of the jaw associated with everolimus: A case report. Mol Clin Oncol. 2017;6(2):255\u20137.","journal-title":"Mol Clin Oncol."},{"key":"657_CR9","doi-asserted-by":"crossref","unstructured":"Azarenko O, Smiyun G, Mah J, et al. \u201cAntiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells.\u201d Mol Cancer Ther. 2014;13(8):2092\u20132103.","DOI":"10.1158\/1535-7163.MCT-14-0265"},{"issue":"21","key":"657_CR10","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","volume":"126","author":"EC Fink","year":"2015","unstructured":"Fink EC, Benjamin LE. The novel mechanism of lenalidomide activity. Blood. 2015;126(21):2366\u20139.","journal-title":"Blood."},{"key":"657_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.217","volume":"4","author":"N S\u00e9v\u00e8re","year":"2013","unstructured":"S\u00e9v\u00e8re N, et al. E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis. 2013;4: e463.","journal-title":"Cell Death Dis"},{"issue":"2","key":"657_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12020-011-9580-0","volume":"41","author":"RS Weinstein","year":"2012","unstructured":"Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41(2):183\u201390. https:\/\/doi.org\/10.1007\/s12020-011-9580-0.","journal-title":"Endocrine"},{"issue":"2","key":"657_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/07357900802208608","volume":"27","author":"BJ Aragon-Ching","year":"2009","unstructured":"Aragon-Ching BJ, Ning Y, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009;27(2):221\u20136.","journal-title":"Cancer Invest"},{"issue":"6","key":"657_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ajoms.2017.06.009","volume":"29","author":"T Komatani","year":"2017","unstructured":"Komatani T, Sonobe J, Takahashi K, et al. Methotrexate-related osteonecrosis of the jaw: Report of two cases. J Oral Maxillofacial Surg Med Pathol. 2017;29(6):546\u20139.","journal-title":"J Oral Maxillofacial Surg Med Pathol"},{"issue":"4","key":"657_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/dj4040041","volume":"4","author":"Y Kwon","year":"2016","unstructured":"Kwon Y, Kim D. \u201c Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ). Dentistry J (Basel). 2016;4(4):41.","journal-title":"Dentistry J (Basel)"},{"issue":"1","key":"657_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5125\/jkaoms.2019.45.1.3","volume":"45","author":"A NifosiFabrizio","year":"2019","unstructured":"NifosiFabrizio A, Zuccarello M, Nifosi L, et al. Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. J Korean Assoc Oral Maxillofac Surg. 2019;45(1):3\u20138.","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"657_CR17","unstructured":"\u201cFDA Adverse Event Reporting System (FAERS) Public Dashboard,\u201d https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"issue":"35","key":"657_CR18","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"657_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.14740\/jocmr2970w","volume":"9","author":"KA Alswat","year":"2017","unstructured":"Alswat KA. Gender Disparities in Osteoporosis. J Clin Med Res. 2017;9(5):382\u20137.","journal-title":"J Clin Med Res"},{"issue":"24","key":"657_CR20","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.3390\/ijerph17249509","volume":"17","author":"A Marcian\u00f2","year":"2020","unstructured":"Marcian\u00f2 A, Guzzo GM, Peditto M, et al. Medication-Related Osteonecrosis of the Jaws and CDK4\/6 Inhibitors: A Recent Association. Int J Environ Res Public Health. 2020;17(24):9509.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"657_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.7150\/jca.17144","volume":"8","author":"L Guo","year":"2017","unstructured":"Guo L, Zhang H, Chen B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer. 2017;8(3):410\u20136.","journal-title":"J Cancer"},{"issue":"3","key":"657_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/diseases6030079","volume":"6","author":"F Ayoade","year":"2018","unstructured":"Ayoade F, Olayiwola A, Li A. Holes in the Jaw\u2014A Report of Two Cases of Periapical Actinomycosis. Diseases. 2018;6(3):79.","journal-title":"Diseases"},{"issue":"4","key":"657_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/adj.12254","volume":"60","author":"R Marino","year":"2015","unstructured":"Marino R, Orlandi F, Arecco F, et al. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J. 2015;60(4):528\u201331.","journal-title":"Aust Dent J"},{"key":"657_CR24","doi-asserted-by":"crossref","unstructured":"Cao Y, Trieu J, Rojas V, et al. \u201cOsteonecrosis of the jaw (ONJ) in radium 223 (Ra223)-treated metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with exposure to zoledronic acid and\/or denosumab. J Clin Oncol. 2020;38(15):5575.","DOI":"10.1200\/JCO.2020.38.15_suppl.5575"},{"key":"657_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","volume":"16","author":"MJ Morris","year":"2019","unstructured":"Morris MJ, Corey E, Guise TA, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019;16:745\u201356.","journal-title":"Nat Rev Urol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-023-00657-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:16:19Z","timestamp":1678086979000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-023-00657-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1186\/s40360-023-00657-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1598822\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This project was submitted for review through Advocate Health and was waived as this study was deemed non-human subject related research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"Dr. Eli Ehrenpreis serves as the Chief Executive Officer of E2Bio Life Sciences, a company that is developing Bocaliner, a medical device to improve the treatment of oral mucositis which is a complication of chemotherapy, patent pending. Dr. Ehrenpreis has no additional competing interests to disclose. Dr. Hardeep S. Ahdi, Dr. Thomas Adam Wichelmann and Dr. Sasirekha Pandravada have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}